AstraZeneca and Bristol Myers Squibb mull $400 billion deal: Report
AstraZeneca is reportedly in discussions to merge with Bristol Myers Squibb in a deal that could value the combined entity at approximately $400 billion. If completed, this would represent one of the largest pharmaceutical mergers in history.
Why it matters
A merger of this scale would significantly reshape the global pharmaceutical landscape, impacting drug development pipelines and market competition in oncology and rare diseases.
U.K. pharmaceutical giant AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb , in a deal that would value the joint company at roughly $400 billion, the Financial Times reported on Sunday.
It's still unclear whether the deal will come together, but the companies have been discussing a merger over the last few months, sources told the FT.
The merger would be one of the largest in history.
AstraZeneca and Bristol Myers Squibb did not immediately respond to a CNBC request for comment.
Last year, AstraZeneca unveiled plans for a direct U.S. listing , aiming to capitalize on stronger valuations in the U.S. market while remaining listed in London.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in